Active, not recruitingPhase 2NCT06187961

HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma

Studying Pediatric hepatocellular carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Tongji Hospital
Principal Investigator
Ze-yang Ding, M.D.
Tongji Hospital
Intervention
Hepatic arterial infusion chemotherapy (HAIC-FOLFOX)(procedure)
Enrollment
44 enrolled
Eligibility
18 years · All sexes
Timeline
20232028

Study locations (1)

Collaborators

Akesobio

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06187961 on ClinicalTrials.gov

Other trials for Pediatric hepatocellular carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Pediatric hepatocellular carcinoma

← Back to all trials